摘要
目的 评价特治星 (哌拉西林/他唑巴坦 )治疗危重病人肺部感染的疗效和安全性 ,并与头孢他啶比较。 方法 特治星组 (A组 )与头孢他啶组 (B组 )各34例 ,A组静滴特治星针4.5g,1次/8h ,B组静注头孢他啶针1.0g,1次/6h ,疗程7 -10d。每组各有30例加用阿米卡星针0.4～0.6g/d。结果 A组治疗有效率82.4 %,细菌清除率78.1%,不良反应发生率2.94 %;B组治疗有效率55.9 %,细菌清除率48.4%,不良反应发生率5.88 %。统计学处理两组治疗有效率、细菌清除率有显著性差异(p<0.05)。结论 特治星治疗危重病人肺部感染临床疗效好 ,细菌清除率高 ,不良反应少 ,尤其是产酶菌引起的感染 ,较头孢他啶更为有效。
Objective To evaluate the effect and safety of tazocin on pulmonary infection of serious patients. Methods 64 patients were randomized into two groups. Group A was treated with tazocin infusion with a dose of 4.5g/8h.Group B was treated with ceftazidime infusion with a dose of 1.0g/6h.Each group had 30 patients to infuse amikacin with a dose of 0.4～0.6/d. All patients was treated 7 to 10 days. Result Group A showed a effective rate of 82.4%, bacteria clearance of 78.1% and adverse reaction incidence of 2.94%. Group b showed a effective rate of 55.9%, bacteria clearance of 48.4% and adverse reaction incidence of 5.88%. Conclusion Tazocin showed a better effect on pulmonary infection of serious patients than ceftazidime.
出处
《浙江临床医学》
2002年第7期483-484,共2页
Zhejiang Clinical Medical Journal
